/ORGO

Organogenesis Holdings Inc

ORGO

$1.49USD↓-2.61%-0.04 today

MARKET CAP

191.7M

P/E (TTM)

—

FWD P/E

—

DAY RANGE

$1 – $2

52W RANGE

$1

$7

AI Summary

Stalk

Sell NowMedium

ORGO remains in a sustained downtrend on both medium- and long-term horizons, trading below all key moving averages with no active bullish patterns. Medium-term bias is bearish given persistent lower highs and lows and resistance at the 21/50 EMA zone. Short-term execution readiness is confirmed by a failed rally into the EMAs and rejection at moving-average resistance. Sell Now is advised at these resistance levels into the ongoing downtrend.

↑Q2 revenue rose 18% QoQ to $42.8 M, indicating sales rebound.
↑Restructuring cuts 138 jobs to save ~$18 M annually.
↓Q2 revenue fell 58% YoY to $42.8 M; advanced wound care sales down 61%.

Full analysis →

Buying

5

institutions

Selling

3

institutions

New Positions

1

this quarter

Filing Period

Q2 2026

latest 13-F

13-F Holdings

Institution↕	Action↕	Shares Held↕	Value↓	Change↕	Chg %↕	Weight↕
BI Blackrock, Inc. Q2 2026	BUY	7.25 M	17.62 M	+2.35 M	+51.7%	0.00%
AC Aqr Capital Management LLC Q2 2026	BUY	3.01 M	7.32 M	+2.13 M	+250.2%	0.00%
RT Renaissance Technologies LLC Q2 2026	SELL	1.02 M	2.47 M	+-51.42 K	-2.4%	0.00%
CA Citadel Advisors LLC Q2 2026	BUY	867.93 K	2.11 M	+323.69 K	+63.5%	0.00%
JC Jpmorgan Chase & Co Q2 2026	BUY	28.69 K	69.43 K	+703.00	+8.3%	0.00%
BH Brevan Howard Capital Management LP Q2 2026	BUYNEW	20.24 K	49.18 K	+20.24 K	+0.0%	0.00%
RC Rockefeller Capital Management L.P. Q2 2026	SELL	3.07 K	7.45 K	+-3.42 K	-51.5%	0.00%
PA Point72 Asset Management, L.P. Q2 2026	SELL	0.00	0.00	+-148.36 K	-100.0%	0.00%